Job leads

http://www.cafepharma.com/cpwire/article/MedReps-Survey-Reveals-Best-Places-to-Work-in-Medical-Sales-in-2017-%28inc.-infographic%29/56971

 

Please post job leads here.

Rats fleeing a sinking ship.

 

PULMONOLOGY SALES HIRES!!! Seeking sales reps in Denver, Minneapolis, Los Angeles, and Chicago. MUST have recent pulmonology call points/contacts IN one of these regions. Minimal travel. Uncapped commission. Great work/life balance and company culture. Opportunity to grow quickly within the organization. Looking at a May 2017 start date! Please sends resumes to Alison.Bridges@kornferry.com

 

https://mallinckrodt.wd5.myworkdayjobs.com/MallinckrodtCareers/fs/refreshFacet/318c8bb6f553100021d223d9780d30be

Mallinckrodt is hiring.

 

Flexion is hiring.

 

FDA Accepts sBLA Filing of Soliris® (Eculizumab) as a Potential Treatment for Patients with Refractory Generalized Myasthenia Gravis (gMG)
March 08, 2017 06:30 AM Eastern Standard Time


NEW HAVEN, Conn.--(BUSINESS WIRE)--Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) announced today that the U.S. Food and Drug Administration (FDA) has accepted for review the Company’s supplemental Biologics License Application (sBLA) to extend the indication for Soliris® (eculizumab) as a potential treatment for patients with refractory generalized myasthenia gravis (gMG) who are anti-acetylcholine receptor (AChR) antibody-positive. The sBLA submission is supported by comprehensive data from the Phase 3 REGAIN study. The FDA set a Prescription Drug User Fee Act (PDUFA) date of October 23, 2017.

 

https://careers-keryx.icims.com/jobs/search?ss=1&searchKeyword=Sales&mobile=false&width=940&height=500&bga=true&needsRedirect=false&jan1offset=-300&jun1offset=-240

Keryx is hiring.

 

UltraGenyx is hiring.

Why Join Us?
Ultragenyx is a clinical stage biotechnology company committed to bringing to market novel products for the treatment of rare and ultra-rare diseases with an initial focus on serious debilitating metabolic genetic diseases. Founded in 2010, the company has rapidly built a diverse portfolio of both large and small molecule candidates with the potential to address diseases for which the unmet medical need is high, the biology for treatment is clear, and for which there are no approved therapies.

For the patients we seek to treat, we recognize that their lives and well-being are dependent upon our efforts to develop new therapies. For this reason, we are passionate about developing these therapies with the utmost urgency and care while ensuring patient access is optimized at the time of approval for these innovative late-stage products.

Now is an exciting and unique opportunity to join a fast growing rare disease global bio-pharmaceutical company in a leadership role.

We are headquartered in Novato, CA, 25 miles north of San Francisco. The North American Commercial Office is based in the heart of the innovative Biotech hub in Brisbane CA, conveniently located within 5 miles of the SFO Airport.

Position Summary:
Ultragenyx is actively building a US Commercial Field Team in anticipation of the approval of their clinical stage therapies. The Commercial Field Team will represent Ultragenyx in the Rare Disease Community. Each Field Team member will be provided a geography of responsibility. We are seeking individuals with the desire to run their own business within a specified geography. These individuals will have strong business acumen, be able to drive change through innovative approaches, demonstrate excellent communication skills and consistently deliver results.

We are seeking to build a Commercial Field Team comprised of individuals who are skilled at running a business and understand the key drivers for business optimization and success. We are not seeking individuals whose general experience is mainly in sales. The ideal candidate will have a successful track record of identifying and harnessing business opportunities for efficient growth across diverse landscapes. This role is a rare and unique opportunity for the individual who excels in a patient focused environment with an unprecedented delivery of results in a service model environment.

The priorities within each geography will vary based upon the local environment. It will be the responsibility of the Commercial Field Team Member to determine what the key priorities are within their geography, create a business plan that is organizationally approved and implement this personally designed plan of action, to the highest standards.


Responsibilities, including but not limited to:

• Serve as territory business owner with a focus upon impact and territory analysis. Other key areas of focus include optimizing: i) patient diagnosis and care, ii) educating and expanding the healthcare provider community, iii) treatment fulfillment and iv) compliance to treatment
• Identify and work to resolve HCP and patient access barriers to care
• Support HCP’s to ensure they have the tools for patient diagnosis and treatment
• Educate HCP’s on disease and product education, patient diagnosis, treatments and treatment fulfillment
• Launch and manage patient engagement programs
• Provide In-Service training to office staff, local training set-up regarding transfusions and self-administered SQ injections
• Build a community based network consisting of treating physicians who diagnose and treat rare diseases
• Educate HCP’s on diagnostic testing opportunities and techniques
• Ensure payer access and reasonable coverage policy with local health plans, that are most relevant to these practices

​

Requirements:

• Minimum - Bachelor’s Degree with 8+ years of science and business skills experience
• Preferred - Master’s Degree in Science or Business, MBA and/or Medical Degree
• Experience in HCP education and promotion, with a track record of success, communicating scientifically complex products to a specialty medical audience
• Broad experience developing and running a business that goes beyond the traditional sales roles in organizations
• Demonstrated success with novel products that are first-in-class and a deep interest in truly advancing the care of Rare Disease patients
• Ability to research and develop external networks to expand the base of physicians involved with patients
• Ability to effectively network with physician societies, engaging them in evaluating new treatment paradigms, patient support programs and care pathways
• Excellent skills in the development of business plans, utilization of resources and budget to optimize patient care within a territory
• Ability to research and problem solve complex issues impacting HCP’s and patient access barriers to care
• Demonstrated experience effectively presenting clinical/scientific information required
• Expert understanding of payer access and reimbursement
• Approximately 30-70% (dependent on geography) travel is required; overnight travel is required as needed

​

 

http://www.seattlegenetics.com/careers/job-opportunities

Seattle Genetics is hiring.

 

https://careers-aclaristx.icims.com/jobs/search?ss=1&searchLocation=12781--

Aclaris Therapeutics is hiring.

 

https://jobs-valeant.icims.com/jobs/search?ss=1&searchCategory=131887&searchLocation=8404--

Valeant is hiring.

 

La Jolla Pharmaceutical is hiring.

http://careers2.hiredesk.net/viewjobs/default.asp?Comp=ventiv&sPERS_ID=&TP_ID=25&JB_ID=&PROJ_ID=&LAN=en-US&CriteriaValue={21236F86-9E2A-4BC7-AF1E-F6A52A7C02CC}

3 of our MSLs went there (so far).

 

Are they hiring reps and more MSLs?

 

https://chj.tbe.taleo.net/chj05/ats/careers/v2/searchResults?org=SUN_PHARMA&cws=41

Sun Pharma is hiring.

 

Territory Business Manager – Nationwide
Job ID: 413
Job Location: United States - Field
Job City:
Date Updated: December 2, 2017

POSITION SUMMARY:
At Intercept, we are working to become a trusted partner for clinicians, payors, policy makers, community representatives and the broader scientific community in underserved, chronic liver disease. We are looking for authentic and experienced Territory Business Managers, who share our passion for liver disease, to lead our effort to become a global leader in improving liver disease. We expect all prospective employees to steadfastly hold our company’s core values of INTEGRITY, EXCELLENCE, COLLABORATION, INNOVATION & PASSION to the highest standards.
The Territory Business Manager is responsible for supporting our stakeholders in improving patient outcomes in the diseases where we provide innovative medicines, by ensuring understanding of the data and appropriate usage, and accelerating patient access. They will be accountable for ensuring that we understand the key stakeholders who care for and support patients and that their voice is heard throughout the company. They will have a key role in developing and executing our territory strategy; strategically working internally in a matrix organization with cross functional leadership; accurately analyzing key business drivers and trend; and ensuring execution of the business plan for both internal and external customer stakeholders.
The successful candidate will also be able to interact significantly with other functional and geographical teams across the company. It is critical that this person is committed to building effective cross-functional and cross-regional partnerships.
The position requires adaptability and the capacity to ‘own’ tasks, problem solve and to see projects through to their end in a flexible and innovative manner.
This role will demand an ability to work strategically and operationally in equal measures and the right person will thrive in ambiguity and possess an entrepreneurial and innovative spirit. There’s a lot to do – so high energy levels and a sense of humor will be required.

ESSENTIAL FUNCTIONS:
• Responsible for achievement of corporate goals in given territory in providing appropriate product and patient access information to appropriate healthcare providers.
• Demonstrates in-depth knowledge of Intercept’s product, patient and HCP issues, the business strategy and competitive environment and stays abreast of key market access issues/trends important for educating customers.
• Demonstrates in-depth knowledge of Intercept’s Patient Access Program & Distribution Models.
• Supports KOL advocacy and executes company sponsored speaker program plan.
• Uses networks and relationships to enhance partnerships by creating opportunities for direct contact between key customers and home office staff.
• Leverages technology best practices, shares technology solutions with others, and uses communication technology to increase efficiency and productivity of territory.
• Communicate frequently with other TBMs across the country and cross functional counterparts such as marketing, sales ops, market access, training, and medical to create alignment of POA plan, focus on strategic drivers, and sharing best practices.
• Acts with an understanding of the healthcare environmental pressures that customers face and seeks decisions that benefit both parties.
• Focuses on goal achievement, demonstrating personal accountability and a commitment to achieving the objectives of the business within appropriate corporate compliance regulations.
• Develops direct relationships with key care providers and patient advocacy groups throughout territory.
• Ensures continuing development of competencies and seeks career growth opportunity where appropriate.
• Other projects as assigned.

QUALIFICATIONS:
• Bachelor’s Degree required.
• Specialty product sales experience required.
• Proven success in a sales role and rare/orphan disease and/or specialty experience for minimum of 3 years preferred.
• Direct experience in informing HCPs on Patient Access Programs and Patient Services strongly preferred.
• Business skills to assess and determine investment levels and be accountable for driving territory results in Primary Biliary Cholangitis (PBC).
• Experience in other commercial leadership roles such as Sales Training, Marketing, or Sales Operations preferred.
• Demonstrated experience achieving compliance of sales and marketing strategies and corporate plan.
• Outstanding customer relationship, interpersonal, and communication skills with the established ability to effectively work with diverse audiences and influence cross functionally.
• Strong analytical skills with the proven ability to effectively analyze data to determine trends and effectively manage the territory budget.
• Advanced level of proficiency with CRM, PowerPoint, Excel, etc.
• Fundamental knowledge of incentive compensation plans.
• Excellent presentation skills are required.

REQUIRED KNOWLEDGE AND ABILITIES:
• Strong verbal and written communication skills are essential.
• Excellent organization, multi-tasking & negotiation skills.
• Exceptional interpersonal skills and problem-solving capabilities.
• Ability to work independently and prioritize with minimal daily instruction.
• Extensive knowledge of compliance requirements for interacting with healthcare providers.

 

Thanks.

 

Stonebridge Biopharma is hiring for their new startup division. Rare Diseases.
Base in the 130k range and 80k bonus with $1200.00 car allowance plus actual stock.

 

Sign us up!!

 

GW Pharmaceuticals is hiring a sale's force. Jobs posted on LinkedIn.

This Cannabis-Based Drug Is On the Verge of Making History
If approved by the FDA, this cannabidiol-based drug may have an opportunity to (partially) reform federal law.

May 20, 2018 at 1:11PM

Every time we turn around, the marijuana industry seems to be making history. Earlier this year, Cronos Group became the very first over-the-counter-listed pot stock to uplist to a more reputable exchange -- the Nasdaq. In January, Vermont became the ninth state to OK the use of recreational marijuana, but it did so entirely through the legislative process, becoming the very first state to do so.

Next month, Canada could become the first developed country in the world to legalize adult-use cannabis. This latter expectation seems to be all but certain, with legal sales expected to commence in August or September.

But it's not just the traditional recreational weed industry that's making history in 2018. One cannabinoid-derived drug, to borrow and modify a phrase from Star Trek, appears set to boldly go where no cannabinoid-based drug has gone before: the pharmacy shelf.

A cannabis-derived drug is very close to making history

GW Pharmaceuticals' (NASDAQ:GWPH) lead drug Epidiolex is currently under review by the U.S. Food and Drug Administration (FDA) as a treatment for two rare types of childhood-onset epilepsy -- Dravet syndrome and Lennox-Gastaut syndrome. Epidiolex utilizes the popular cannabinoid known as cannabidiol (CBD), which is often revered for its medical benefits. Unlike tetrahydrocannabinol (THC), which is the component of the cannabis plant that gets you "high," CBD does no such thing, making it a potentially attractive option for drug developers and regulators to consider.

To date, the FDA never has approved a cannabinoid-based drug. Though the drug regulatory agency has given the green light to synthetic forms of THC, no cannabinoid-based medications have ever been granted access to pharmacy shelves with the approval of the FDA.

In one pivotal-stage study for Dravet syndrome patients, GW Pharmaceuticals' lead drug demonstrated a 39% reduction in seizure frequency relative to baseline, which was three times better than the 13% reduction achieved from the placebo. There are no FDA-approved treatments for Dravet syndrome, which could allow Epidiolex to become something really special for the 1 person in every 40,000 people who suffer from it in the United States.

Epidiolex continues to build its resume
This past week, GW Pharmaceuticals' Epidiolex continued to add to its impressive resume after data was published in the prestigious New England Journal of Medicine that highlighted the results from one of its phase 3 trials involving Lennox-Gastaut syndrome (LGS) patients. An estimated 14,000 to 18,500 patients suffer from LGS in the U.S.

The study involved 225 LGS patients, of which 76 were assigned to the higher-dose Epidiolex arm, 73 were assigned to the lower-dose Epidiolex arm, and 76 to the placebo group. During a four-week baseline period, 85 drop seizures -- a type of seizure LGS patients experience that results in the sudden loss of muscle strength -- were recorded. However, following a 14-week treatment period, drop-seizure frequency declined by 17.2% in the placebo group, 37.2% in the low-dose Epidiolex arm, and an impressive 41.9% in the high-dose Epidiolex arm. It's another clear feather in the cap for Epidiolex.

Speaking of feathers in its cap, GW Pharmaceuticals also recently announced late last month that the FDA's advisory panel had recommended Epidiolex for approval by a unanimous vote. While the FDA isn't obligated to follow the advice of its advisory panel, it does more often than not. Should Epidiolex get the green light from the FDA on or before its June 27, 2018 PDUFA decision date, it will make history.

 

Just got their approval.